.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Merck
Moodys
Cipla
Medtronic
Argus Health
Mallinckrodt
Dow
Queensland Health
Boehringer Ingelheim

Generated: September 24, 2017

DrugPatentWatch Database Preview

Diclegis Drug Profile

« Back to Dashboard

Which patents cover Diclegis, and what generic Diclegis alternatives are available?

Diclegis is a drug marketed by Duchesnay and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-one patent family members in thirty-seven countries.

The generic ingredient in DICLEGIS is doxylamine succinate; pyridoxine hydrochloride. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the doxylamine succinate; pyridoxine hydrochloride profile page.

Summary for Tradename: Diclegis

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:Diclegis at DailyMed

Pharmacology for Tradename: Diclegis

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Duchesnay
DICLEGIS
doxylamine succinate; pyridoxine hydrochloride
TABLET, DELAYED RELEASE;ORAL021876-001Apr 8, 2013ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Duchesnay
DICLEGIS
doxylamine succinate; pyridoxine hydrochloride
TABLET, DELAYED RELEASE;ORAL021876-001Apr 8, 2013ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for DICLEGIS

Drugname Dosage Strength RLD Submissiondate
doxylamine succinate and pyridoxine hydrochlorideDelayed-release Tablets10 mg/10 mgDiclegis8/1/2013

International Patent Family for Tradename: DICLEGIS

Country Document Number Estimated Expiration
Belgium1016043► Subscribe
Denmark1397133► Subscribe
Japan4242763► Subscribe
Uruguay27352► Subscribe
Saudi Arabia1764► Subscribe
Finland20021708► Subscribe
China1447694► Subscribe
Turkey200201685► Subscribe
European Patent Office1397133► Subscribe
South Korea100527985► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Teva
Express Scripts
Daiichi Sankyo
Fish and Richardson
Harvard Business School
Baxter
AstraZeneca
Deloitte
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot